<DOC>
	<DOCNO>NCT00390910</DOCNO>
	<brief_summary>This study aim evaluate safety , reactogenicity immunogenicity GlaxoSmithKline ( GSK ) BiologicalsÂ´ 10-valent pneumococcal conjugate vaccine co-administered diphtheria , tetanus , acellular pertussis-hepatitis B virus-inactivated polio virus/Haemophilus influenzae type b ( DTPa-HBV-IPV/Hib ) vaccine preterm infant 3-dose primary immunization course first 6 month life . This protocol post deal objective &amp; outcome measure primary study . The objective &amp; outcome measure Booster study present separate protocol posting ( NCT number = 00609492 )</brief_summary>
	<brief_title>Study Evaluate Safety Immunogenicity 10-valent Pneumococcal Conjugate Vaccine Preterm Infants</brief_title>
	<detailed_description>The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol A male female , include , 816 week ( 56118 day ) age time first vaccination . Written inform consent obtain parent guardian subject . Born gestation period &gt; 27 week ( least 189 day ) . If full term bear , healthy subject establish medical history clinical examination enter study If premature , medically stable condition ( require significant medical support ongoing management debilitate disease demonstrate clinical course sustain recovery ) . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug birth first vaccine dose . Planned administration/administration vaccine foreseen study protocol , period start one month first dose vaccine Visit 6 . Previous vaccination diphtheria , tetanus , pertussis , polio , hepatitis B , Haemophilus influenzae type b , Neisseria meningitidis and/or Streptococcus pneumoniae exception vaccine first dose give within first two week life accord national recommendation History intercurrent diphtheria , tetanus , pertussis , hepatitis B , polio , Haemophilus influenzae type b disease , Neisseria meningitidis . History allergic disease reaction likely exacerbate component vaccine . History neurologic disorder seizure ( criterion apply subject single , uncomplicated febrile convulsion past ) . Acute disease time enrolment . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination A family history congenital hereditary immunodeficiency . Major congenital defect serious chronic illness . Administration immunoglobulins , exception monoclonal antibody RSV , and/or blood product within one month precede first dose study vaccine plan administration active phase study .</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Preterm</keyword>
	<keyword>Safety</keyword>
	<keyword>Pneumococcal disease</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>